Copertina

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Cindy L. Williams, Joanna Billings, Harriet McGowan, Rebecca McDevitt, Charles R. Esther, Cameron J. McKinzie, William S. Wilson, Charissa W. Kam
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Pediatric Pulmonology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series
di: Charissa W. Kam, et al.
Pubblicazione: (2024)

Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis
di: Emma M. Tillman, et al.
Pubblicazione: (2025)

Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
di: Sara Kümmerli, et al.
Pubblicazione: (2026)

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
di: Burcu Uzunoglu, et al.
Pubblicazione: (2025)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis
di: Senthilkumar Sankararaman, et al.
Pubblicazione: (2025)

Effects of Elexacaftor‐Tezacaftor‐Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis
di: Guillaume Petit, et al.
Pubblicazione: (2025)

Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
di: Kimberly Pasley, et al.
Pubblicazione: (2024)

Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years
di: Rebecca S. Pettit, et al.
Pubblicazione: (2025)

Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor
di: Richard De Vuyst, et al.
Pubblicazione: (2024)

Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
di: Cameron J. McKinzie, et al.
Pubblicazione: (2024)

Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis
di: Adi Dagan, et al.
Pubblicazione: (2026)

A Tale of Two Infants: Off‐Label Use of Elexacaftor/Tezacaftor/Ivacaftor in Early Cystic Fibrosis Treatment
di: Nour K. Kadouh, et al.
Pubblicazione: (2025)

Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis
di: Emma R. Lyons, et al.
Pubblicazione: (2025)

The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study
di: Sasha‐Jane Abi‐Aad, et al.
Pubblicazione: (2026)

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study
di: Lauren J. Clayton, et al.
Pubblicazione: (2025)

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis
di: Christos Kogias, et al.
Pubblicazione: (2026)

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor
di: Madison Pranske, et al.
Pubblicazione: (2026)

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
di: Sonia Graziano, et al.
Pubblicazione: (2025)

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
di: Esben Herborg Henriksen, et al.
Pubblicazione: (2025)

Effects of an Exercise Intervention on Exercise Capacity in Adults With Cystic Fibrosis: A Quasi‐Experimental Study Comparing Individuals Treated With and Without Elexacaftor/Tezacaftor/Ivacaftor
di: Wolfgang Gruber, et al.
Pubblicazione: (2025)

Crushing Elexacaftor/Tezacaftor/Ivacaftor Oral Granules for Gastrostomy Tube Administration
di: Alexander S. Kim, et al.
Pubblicazione: (2025)

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series
di: Shanal Kumar, et al.
Pubblicazione: (2024)

Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
di: Jochen G. Mainz, et al.
Pubblicazione: (2026)

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center
di: Lena Papadakis, et al.
Pubblicazione: (2024)

Variable Response to Elexacaftor/Tezacaftor/Ivacaftor in [L467F;F508del] Homozygous Patients: A Case Series
di: Meltem Akgül Erdal, et al.
Pubblicazione: (2026)

Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy
di: Samya Z. Nasr, et al.
Pubblicazione: (2026)

Initial Antibiotic Selection Based on Microbiologic History in Pediatric Cystic Fibrosis‐Related Pulmonary Exacerbations
di: Jillian Grapsy, et al.
Pubblicazione: (2025)

Elexacaftor/Tezacaftor/Ivacaftor Effect on a Patient With Rare Compound Heterozygous CFTR Splice Variant Genotype C.[1393‐1G>A;2988+1G>A]
di: Maria Moustaki, et al.
Pubblicazione: (2025)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
di: Don S. Urquhart, et al.
Pubblicazione: (2024)

Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
di: A. M. Zwitserloot, et al.
Pubblicazione: (2025)

Effects of Therapeutic Antibiotic Exposure on the Oropharyngeal and Fecal Microbiota in Infants With Cystic Fibrosis
di: Hillary S. Hayden, et al.
Pubblicazione: (2025)

Tobramycin Pharmacokinetics in Pediatric People With Cystic Fibrosis on Maintenance Azithromycin
di: Chelsea Flora, et al.
Pubblicazione: (2026)

Home Microbiological Sampling in a Pediatric Cystic Fibrosis Population: Pandemic Implementation and Ongoing Use
di: Khizra Farhan Ahmad, et al.
Pubblicazione: (2026)

Microbiological Profile of Airway in Indian Children With Cystic Fibrosis: A Multicenter Prospective Cohort Study
di: Prawin Kumar, et al.
Pubblicazione: (2025)

E‐Cigarettes and Cystic Fibrosis—Current Perceptions and Future Directions
di: Maryam Sahibqran, et al.
Pubblicazione: (2024)

Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis
di: Lauren N. Kormelink, et al.
Pubblicazione: (2024)

Associations Between Socioeconomic Status and Adherence to Medications in People With Cystic Fibrosis
di: Gabriela R. Oates, et al.
Pubblicazione: (2025)

Induced Sputum: A Valuable Tool for Assessing Cellular and Microbiological Characteristics in Cystic Fibrosis Expectorating Teenagers
di: M. Guedes, et al.
Pubblicazione: (2025)

A Joint Conversation: People With Cystic Fibrosis' Perception of Healthcare Teams' Knowledge, Comfort, and Barriers in Discussing Substance Use
di: Sanaz Vaziri, et al.
Pubblicazione: (2025)

Feeding the Need: A Study on Food Security Among People With Cystic Fibrosis in Turkey
di: Damla Kocaman, et al.
Pubblicazione: (2025)